摘要
16例经组织学或细胞学确诊的肺癌并胸水患者接受了共41个疗程的顺氯氨铂“双途经化疗”(简称DDP“TRC”)。DDP按100～150mg/m^2溶解后由胸腔注入,同时以硫代硫酸钠(STS)静脉滴注以解除全身毒性。每四周一个疗程。在不同时间点取胸水、血和尿标本以无火焰原子吸收光谱法检测总铂的药物浓度。胸腔内灌注后,DDP在胸水中的半衰期为4.7955±1.2203小时,胸水和血浆中的DDP峰浓度之比为43.98,用药后24小时尿内DDP的累积排泄量为用药总量的34.87％,用STS可使DDP在血浆中的消除和尿中的排泄明显加快而对其在胸水中的DDP影响不大。在16例患者的疗效评价中,显效率12.5％,有效率68.75％,中数缓解期>5个月。加用STS使DDP对肾脏和骨髓的毒性减轻。研究结果表明:DDP双途径化疗有其药代动力学方面的优越性,可在用大剂量DDP治疗癌性胸水中减少全身毒性并获得较好疗效。
Sixteen patients with cytologically or hisologically comfirmed malginant pleural effusion from carcinoma of the lung have received 41 courses of intrapleural DDP. DDP(100- isomg/m 2) was administered intrapleurally with concurrent i. v. infusion of sodium thiosulfate. Courses were repeated in 4 - week intervals. Total platinum in the pleural pleural effusion, serum and urine were measured with flameless atomic absorption spectram-ometer.The results of the laboratory examination revealed ? The T1/2 of DDP was 4.7955± 1.2203 hours in the pleural effusion. The ratio of peak concentration of DDP in pleural effusion versus plasma was 43.98 . The cumulative excretion of DDP within 24 ho urs accounted for 34.87 % of the total administered dose . STS might quiken the elimi- nation of DDP from the blood and excretion in the urine, while the DDP contents in pleural effusion were not remarkably affected . Clinical studies revealed that, of the 16 cases, 12.5% and 68.5% of cases achieved 'remarkable response ' and 'response ' respectively. The median response duration was over 5 months, The concurrent systemic adminitration of STS might reduce the nephro-and myelotoxicity of DDP.This study demonstrates a pharmacokinetic advantag of DDP 'TRC' and an effective-onerss against pleural effusion from lung cancer with minimal systemic toxicity .
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1990年第3期173-177,共5页
Chinese Journal of Cancer
